Global Anti-PCSK9 Monoclonal Antibody Market Size, Share and Trends Analysis Report, By Type (Alizumab and Evolocumab) and By Application (Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Others), Forecast Period (2022-2028)

The global anti-PCSK9 monoclonal antibody market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Monoclonal antibodies are immune system proteins that are directed towards a specific antigen in the body. Monoclonal antibodies are utilized for diagnostic and therapeutic purposes in immunotherapy. PCSK9 stands for proprotein convertase subtilisin/Kexin type-9, a serine protease that belongs to the subtilisin family. The anti-PCSK9 monoclonal antibody market is primarily driven by rising obesity rates globally, increased junk food consumption, and a lack of regular exercise. Moreover, an increasing number of individuals suffering from primary hypercholesterolemia and atherosclerotic cardiovascular disease is also significantly supporting the growth of the market.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

• In November 2021, MK-0616, a novel PCSK9 inhibitor under investigation had cleared clinical trials, with early evidence revealing LDL cholesterol reductions even in people on statins. MK-0616 is a PCSK9 inhibitor that is orally bioavailable and has nonclinical pharmacokinetic and safety features that justify a clinical trial.
• In August 2020, Hamad Medical Corp. studied PCSK9 monoclonal antibodies as a standalone therapeutic agent or as an add-on therapy to standard LLT for the treatment of dyslipidemia. They were found to be efficacious and safe in treating familial and non-familial hypercholesterolemia.
• In March 2020, Sanofi and Regeneron Pharmaceuticals, Inc., announced that a clinical trial for Kevzara (sarilumab) in patients hospitalized with severe COVID-19 infection has begun. Kevzara is a completely human monoclonal antibody that binds to and blocks the IL-6 receptor, inhibiting the interleukin-6 (IL-6) pathway.
• In March 2019, Innovent Biologics, Inc. (Innovent) announced that the first patient in a Phase-II clinical study of IBI306, a recombinant fully human anti-proprotein convertase substilisin/kexin type-9 (anti-PCSK9) monoclonal antibody for the treatment of hypercholesterolemia, has been dosed successfully.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

·         Competitive Landscape- Sanofi S.A., Regeneron Pharmaceuticals, Inc.,  Amgen Inc.,  Thermo Fisher Scientific,  and Abnova Corp., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anti-PCSK9 Monoclonal Antibody Market Report by Segment

By Type

• Alizumab
• Evolocumab

By Application

• Hypercholesterolemia
• Atherosclerotic Cardiovascular Disease
• Others

Global Anti-PCSK9 Monoclonal Antibody Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa